PRQRNasdaqPharmaceutical PreparationsFiscal year ends December 31

ProQR Therapeutics N.V.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 12, 2026

$1.31+0.00 (0.00%)

Close on Oct 19, 2026

ProQR Therapeutics N.V. income statement

Annual Quarterly TTM

EUR USD

Millions of EUR, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31
Revenue	16	19	6.51	3.59	1.34	–	–	–	–	–	–
Research & Development	45	36	25	51	42	38	46	30	31	32	23
Operating Expenses	60	50	41	70	60	52	59	42	42	41	30
Operating Income	-43	-30	-32	-65	-57	-42	-57	-36	-40	-40	-27
Interest Expense	1.29	1.08	1.46	5.13	3.41	4.03	1.08	–	–	–	–
Interest & Investment Income	2.33	3.25	2.59	4.86	1.52	0.31	1.49	–	–	–	–
Income from Equity Investments	–	–	–	-0.01	-0.22	-0.32	0.43	–	–	–	–
Pretax Income	-42	-28	-28	-64	-61	-46	-57	-37	-44	-39	-21
Income Tax Expense	0.02	-0.20	-0.08	0.10	0.12	0.12	0.13	0.00	0.00	–	–
Net Income incl. Noncontrolling Interests	-42	-28	-28	-64	-61	-47	-57	-37	-44	-39	-21
Minority Interest in Earnings	–	–	0.38	0.22	-0.06	-0.05	-0.27	-0.19	-0.04	–	–
Net Income	-42	-28	-28	-64	-61	-47	-56	-37	-44	-39	-21
Net Income to Common	-42	-28	-28	-64	-61	-47	-56	-37	-44	-39	-21
EPS (Basic)(per share)	-0.40	-0.32	-0.35	-0.90	-0.95	-0.93	-1.38	-1.08	-1.72	-1.67	-0.89
EPS (Diluted)(per share)	-0.40	-0.32	-0.35	-0.90	-0.95	-0.93	-1.38	-1.08	-1.72	-1.67	-0.89
Shares Outstanding (Basic, Weighted)(shares)	105	86	81	72	64	50	41	34	25	23	23
Shares Outstanding (Diluted, Weighted)(shares)	105	86	81	72	64	50	41	34	25	23	23
EBITDA	–	–	–	–	-55	-40	-55	-35	-39	-38	-27

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -233.4%
Net margin: -228.9%
Return on equity, FY2025: -61.2%

Financial strength

Current ratio: 3.49
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 335.9%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –

Valuation ratios need the share price and fill in once daily prices are connected.